{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:02:14Z","timestamp":1774263734801,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AIRC","award":["IG15232"],"award-info":[{"award-number":["IG15232"]}]},{"name":"AIRC","award":["IG21408"],"award-info":[{"award-number":["IG21408"]}]},{"name":"AIRC","award":["IG23095"],"award-info":[{"award-number":["IG23095"]}]},{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","award":["UNITO-CLL01"],"award-info":[{"award-number":["UNITO-CLL01"]}],"id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Torino","award":["Local funds ex60%"],"award-info":[{"award-number":["Local funds ex60%"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including CLL. The purpose of this study was to evaluate the anti-tumor effects of selinexor, used in combination with chemotherapy drugs (i.e. fludarabine and bendamustine) or with the PI3K\u03b4 inhibitor idelalisib in CLL. Our results showed a significant decrease in CLL cell viability after treatment with selinexor-containing drug combinations compared to each single compound, with demonstration of synergistic cytotoxic effects. Interestingly, this drug synergism was exerted also in the presence of the protective effect of stromal cells. From the molecular standpoint, the synergistic cytotoxic activity of selinexor plus idelalisib was associated with increased regulatory effects of this drug combination on the tumor suppressors FOXO3A and IkB\u03b1 compared to each single compound. Finally, selinexor was also effective in potentiating the in vivo anti-tumor effects of the PI3K\u03b4 inhibitor in mice treated with the drug combination compared to single agents. Our data provide preclinical evidence of the synergism and potential efficacy of a combination treatment targeting XPO1 and PI3K\u03b4 in CLL.<\/jats:p>","DOI":"10.1038\/s41598-023-44039-0","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T16:01:58Z","timestamp":1696694518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Candida","family":"Vitale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Griggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Todaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Boccellato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Perutelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Arruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Vaisitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitar G.","family":"Efremov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Deaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosef","family":"Landesman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Coscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"44039_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101\u2013105. https:\/\/doi.org\/10.1038\/nature10113 (2011).","journal-title":"Nature"},{"key":"44039_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SE Herman","year":"2010","unstructured":"Herman, S. E. et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116, 2078\u20132088. https:\/\/doi.org\/10.1182\/blood-2010-02-271171 (2010).","journal-title":"Blood"},{"key":"44039_CR3","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel, J. et al. The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603\u20133612. https:\/\/doi.org\/10.1182\/blood-2011-05-352492 (2011).","journal-title":"Blood"},{"key":"44039_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563\u2013574. https:\/\/doi.org\/10.1182\/blood-2010-05-284984 (2011).","journal-title":"Blood"},{"key":"44039_CR5","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman, S. E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287\u20136296. https:\/\/doi.org\/10.1182\/blood-2011-01-328484 (2011).","journal-title":"Blood"},{"key":"44039_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14656566.2017.1293655","volume":"18","author":"C Vitale","year":"2017","unstructured":"Vitale, C. et al. Magic pills: New oral drugs to treat chronic lymphocytic leukemia. Expert Opin. Pharmacother. 18, 411\u2013425. https:\/\/doi.org\/10.1080\/14656566.2017.1293655 (2017).","journal-title":"Expert Opin. Pharmacother."},{"key":"44039_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/jco.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach, J. A. et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J. Clin. Oncol. 35, 1437\u20131443. https:\/\/doi.org\/10.1200\/jco.2016.70.2282 (2017).","journal-title":"J. Clin. Oncol."},{"key":"44039_CR8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044","author":"S O'Brien","year":"2018","unstructured":"O\u2019Brien, S. et al. Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: A 5-year experience. Blood https:\/\/doi.org\/10.1182\/blood-2017-10-810044 (2018).","journal-title":"Blood"},{"key":"44039_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.cd-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery, P. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 9, 342\u2013353. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-1119 (2019).","journal-title":"Cancer Discov."},{"key":"44039_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung, H. Y. & Chook, Y. M. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin. Cancer Biol. 27, 52\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2014.03.002 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"44039_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","volume":"14","author":"JS Walker","year":"2021","unstructured":"Walker, J. S. et al. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J. Hematol. Oncol. 14, 17. https:\/\/doi.org\/10.1186\/s13045-021-01032-2 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"44039_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner, J. G., Dawson, J. & Sullivan, D. M. Nuclear export of proteins and drug resistance in cancer. Biochem. Pharmacol. 83, 1021\u20131032. https:\/\/doi.org\/10.1016\/j.bcp.2011.12.016 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"44039_CR13","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","volume":"129","author":"J Kuruvilla","year":"2017","unstructured":"Kuruvilla, J. et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129, 3175\u20133183. https:\/\/doi.org\/10.1182\/blood-2016-11-750174 (2017).","journal-title":"Blood"},{"key":"44039_CR14","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella, R. et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621\u20134634. https:\/\/doi.org\/10.1182\/blood-2012-05-429506 (2012).","journal-title":"Blood"},{"key":"44039_CR15","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1091\/mbc.E12-01-0045","volume":"23","author":"D Xu","year":"2012","unstructured":"Xu, D., Grishin, N. V. & Chook, Y. M. NESdb: A database of NES-containing CRM1 cargoes. Mol. Biol. Cell 23, 3673\u20133676. https:\/\/doi.org\/10.1091\/mbc.E12-01-0045 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"44039_CR16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/leu.2014.9","volume":"28","author":"Y Zhong","year":"2014","unstructured":"Zhong, Y. et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia 28, 1158\u20131163. https:\/\/doi.org\/10.1038\/leu.2014.9 (2014).","journal-title":"Leukemia"},{"key":"44039_CR17","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing, Z. A. et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood 125, 3128\u20133132. https:\/\/doi.org\/10.1182\/blood-2015-01-621391 (2015).","journal-title":"Blood"},{"key":"44039_CR18","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/jco.2016.67.6346","volume":"34","author":"MM Gounder","year":"2016","unstructured":"Gounder, M. M. et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J. Clin. Oncol. 34, 3166\u20133174. https:\/\/doi.org\/10.1200\/jco.2016.67.6346 (2016).","journal-title":"J. Clin. Oncol."},{"key":"44039_CR19","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon, R. et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood 129, 3165\u20133174. https:\/\/doi.org\/10.1182\/blood-2016-11-750158 (2017).","journal-title":"Blood"},{"key":"44039_CR20","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.Ccr-21-3867","volume":"28","author":"DM Stephens","year":"2022","unstructured":"Stephens, D. M. et al. Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study. Clin. Cancer Res. 28, 3242\u20133247. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3867 (2022).","journal-title":"Clin. Cancer Res."},{"key":"44039_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455 (2019).","journal-title":"N. Engl. J. Med."},{"key":"44039_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki, S. et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 396, 1563\u20131573. https:\/\/doi.org\/10.1016\/s0140-6736(20)32292-3 (2020).","journal-title":"Lancet"},{"key":"44039_CR23","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/s2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7, e511\u2013e522. https:\/\/doi.org\/10.1016\/s2352-3026(20)30120-4 (2020).","journal-title":"Lancet Haematol."},{"key":"44039_CR24","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1182\/blood-2008-06-165068","volume":"113","author":"M Niedermeier","year":"2009","unstructured":"Niedermeier, M. et al. Isoform-selective phosphoinositide 3\u2032-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: A novel therapeutic approach. Blood 113, 5549\u20135557. https:\/\/doi.org\/10.1182\/blood-2008-06-165068 (2009).","journal-title":"Blood"},{"key":"44039_CR25","doi-asserted-by":"publisher","first-page":"29833","DOI":"10.18632\/oncotarget.4006","volume":"6","author":"M Rigoni","year":"2015","unstructured":"Rigoni, M. et al. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget 6, 29833\u201329846. https:\/\/doi.org\/10.18632\/oncotarget.4006 (2015).","journal-title":"Oncotarget"},{"key":"44039_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122883","author":"C Vitale","year":"2021","unstructured":"Vitale, C. et al. Targeting HIF-1\u03b1 regulatory pathways as a strategy to hamper tumor-microenvironment interactions in CLL. Cancers https:\/\/doi.org\/10.3390\/cancers13122883 (2021).","journal-title":"Cancers"},{"key":"44039_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.bbamcr.2011.03.010","volume":"1978\u20131986","author":"X Zhang","year":"1813","unstructured":"Zhang, X., Tang, N., Hadden, T. J. & Rishi, A. K. Akt, FoxO and regulation of apoptosis. Biochim. Biophys. Acta 1978\u20131986, 2011. https:\/\/doi.org\/10.1016\/j.bbamcr.2011.03.010 (1813).","journal-title":"Biochim. Biophys. Acta"},{"key":"44039_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","volume":"10","author":"I Kapoor","year":"2019","unstructured":"Kapoor, I. et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 10, 924. https:\/\/doi.org\/10.1038\/s41419-019-2158-0 (2019).","journal-title":"Cell Death Dis."},{"key":"44039_CR29","doi-asserted-by":"publisher","first-page":"30773","DOI":"10.18632\/oncotarget.25637","volume":"9","author":"T Kashyap","year":"2018","unstructured":"Kashyap, T. et al. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget 9, 30773\u201330786. https:\/\/doi.org\/10.18632\/oncotarget.25637 (2018).","journal-title":"Oncotarget"},{"key":"44039_CR30","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1158\/1078-0432.ccr-16-3083","volume":"23","author":"DR Liston","year":"2017","unstructured":"Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: A guide for nonclinical studies. Clin. Cancer Res. 23, 3489\u20133498. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-3083 (2017).","journal-title":"Clin. Cancer Res."},{"key":"44039_CR31","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","volume":"114","author":"JA Burger","year":"2009","unstructured":"Burger, J. A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. The microenvironment in mature B-cell malignancies: A target for new treatment strategies. Blood 114, 3367\u20133375. https:\/\/doi.org\/10.1182\/blood-2009-06-225326 (2009).","journal-title":"Blood"},{"key":"44039_CR32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3324\/haematol.2019.217430","volume":"105","author":"V Griggio","year":"2020","unstructured":"Griggio, V. et al. HIF-1alpha is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica 105, 1042\u20131054. https:\/\/doi.org\/10.3324\/haematol.2019.217430 (2020).","journal-title":"Haematologica"},{"key":"44039_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/leu.2011.12","volume":"25","author":"M Coscia","year":"2011","unstructured":"Coscia, M. et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 25, 828\u2013837. https:\/\/doi.org\/10.1038\/leu.2011.12 (2011).","journal-title":"Leukemia"},{"key":"44039_CR34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-018-1043-6","volume":"9","author":"M Xie","year":"2019","unstructured":"Xie, M. et al. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a\/Bim axis and serves as a direct target for resistance reversal. Cell Death Dis. 9, 1013. https:\/\/doi.org\/10.1038\/s41419-018-1043-6 (2019).","journal-title":"Cell Death Dis."},{"key":"44039_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2141.2011.08951.x","volume":"156","author":"A Obrador-Hevia","year":"2012","unstructured":"Obrador-Hevia, A., Serra-Sitjar, M., Rodr\u00edguez, J., Villalonga, P. & Fern\u00e1ndez de Mattos, S. The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival. Br. J. Haematol. 156, 334\u2013345. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08951.x (2012).","journal-title":"Br. J. Haematol."},{"key":"44039_CR36","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1101\/gad.1662308","volume":"22","author":"HC Dan","year":"2008","unstructured":"Dan, H. C. et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 22, 1490\u20131500. https:\/\/doi.org\/10.1101\/gad.1662308 (2008).","journal-title":"Genes Dev."},{"key":"44039_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01003-6","author":"Z Xu","year":"2023","unstructured":"Xu, Z. et al. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia. Clin. Exp. Med. https:\/\/doi.org\/10.1007\/s10238-023-01003-6 (2023).","journal-title":"Clin. Exp. Med."},{"key":"44039_CR38","unstructured":"U.S. Food and Drug Administration. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Hematologic Malignancies - Oncologic Drugs Advisory Committee Meeting. https:\/\/www.fda.gov\/media\/157762\/download (2022)."},{"key":"44039_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226 (2014).","journal-title":"N. Engl. J. Med."},{"key":"44039_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal, A. K. et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583 (2014).","journal-title":"N. Engl. J. Med."},{"key":"44039_CR41","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling, M. et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann. Oncol. 28, 2169\u20132178. https:\/\/doi.org\/10.1093\/annonc\/mdx289 (2017).","journal-title":"Ann. Oncol."},{"key":"44039_CR42","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn, I. W. et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132, 2446\u20132455. https:\/\/doi.org\/10.1182\/blood-2018-05-850461 (2018).","journal-title":"Blood"},{"key":"44039_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/jco.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn, I. W. et al. DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J. Clin. Oncol. 37, 912\u2013922. https:\/\/doi.org\/10.1200\/jco.18.00915 (2019).","journal-title":"J. Clin. Oncol."},{"key":"44039_CR44","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398 (2018).","journal-title":"Blood"},{"key":"44039_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2404457","volume":"21","author":"P Ghia","year":"2007","unstructured":"Ghia, P. et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 21, 1\u20133. https:\/\/doi.org\/10.1038\/sj.leu.2404457 (2007).","journal-title":"Leukemia"},{"key":"44039_CR46","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","volume":"108","author":"AJ Johnson","year":"2006","unstructured":"Johnson, A. J. et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108, 1334\u20131338. https:\/\/doi.org\/10.1182\/blood-2005-12-011213 (2006).","journal-title":"Blood"},{"key":"44039_CR47","doi-asserted-by":"publisher","first-page":"11713","DOI":"10.1073\/pnas.0604564103","volume":"103","author":"XJ Yan","year":"2006","unstructured":"Yan, X. J. et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 103, 11713\u201311718. https:\/\/doi.org\/10.1073\/pnas.0604564103 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"44039_CR48","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/leu.2016.333","volume":"31","author":"MJ Carter","year":"2017","unstructured":"Carter, M. J. et al. PI3K\u03b4 inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia 31, 1423\u20131433. https:\/\/doi.org\/10.1038\/leu.2016.333 (2017).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44039-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:03:11Z","timestamp":1700330591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44039-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44039"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44039-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.V. has received consultancy fees from Abbvie, Janssen and Astra Zeneca. Y.L. was an employee of Karyopharm Therapeutics Inc. M.C. received honoraria from Janssen, Gilead, Abbvie, Shire, Astrazeneca and research support from Janssen, Abbvie and Karyopharm Therapeutics. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16950"}}